Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesThiazolides: a new class of drugs for the treatment of chronic hepatitis B and C
Future Microbiology, 09/25/08
Rossignol JF et al. - In preliminary open-label studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss or seroconversion of hepatitis B e antigen in the majority of patients, as well as hepatitis B surface antigen in approximately a quarter of patients. In Phase II studies of patients with chronic hepatitis C genotype 4, nitazoxanide combined with peginterferon alfa-2a, with or without ribavirin, increased the sustained virologic response rate to 79-80 versus 50% with peginterferon plus ribavirin standard of care.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valsartan plus hydrochlorothiazide for first-line therapy in hypertension
Expert Review of Cardiovascular Therapy , 12/11/09
Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease
Expert Opinion in Pharmacotherapy, 12/11/09
Zoledronic acid: an unending tale for an antiresorptive agent
Expert Opinion in Pharmacotherapy, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor